Evolution of the average Target Price on MERCK & CO., INC. |
|
|
Target Price consensus revisions : last 18 months |
|
|
Recommendations (Chart) MERCK & CO., INC. |
|
|
Analyst Recommendations on MERCK & CO., INC. |
|
|
| |
|
|
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022 |
|
MERCK AND COMPANY Leader in oncology, modest valuation |
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
26 |
Last Close Price |
93,55 $ |
Average target price |
96,04 $ |
Spread / Average Target |
2,67% |
High Price Target |
115,00 $ |
Spread / Highest target |
22,9% |
Low Price Target |
76,00 $ |
Spread / Lowest Target |
-18,8% |
Consensus revision (last 18 months)
|